It has been shown recently that some analogues of clinically ineffective trans-diamminedichloroplatinum (II) (transplatin) exhibit antitumor activity. This finding has inverted the empirical structure-antitumor activity relationships delineated for platinum(II) complexes, according to which only the cis geometry of leaving ligands in the bifunctional platinum complexes is therapeutically active. As a result, interactions of trans platinum compounds with DNA, which is the main pharmacological target of platinum anticancer drugs, are of great interest. The present paper describes the DNA binding of antitumor trans-[PtCl(2)(E-imino ether)(2)] complex (trans-EE) in a cell-free medium, which has been investigated using three experimental approaches. They involve thiourea as a probe of monofunctional DNA adducts of platinum (II) complexes with two leaving ligands in the trans configuration, ethidium bromide as a probe for distinguishing between monofunctional and bifunctional DNA adducts of platinum complexes and HPLC analysis of the platinated DNA enzymatically digested to nucleosides. The results show that bifunctional trans-EE preferentially forms monofunctional adducts at guanine residues in double-helical DNA even when DNA is incubated with the platinum complex for a relatively long time (48 h at 37 degrees C in 10 mM NaCIO(4). It implies that antitumor trans-EE modifies DNA in a different way than clinically ineffective transplatin, which forms prevalent amount of bifunctional DNA adducts after 48 h. This result has been interpreted to mean that the major adduct of trans-EE, occurring in DNA even after long reaction times, is a monofunctional adduct in which the reactivity of the second leaving group is markedly reduced. It has been suggested that the different properties of the adducts formed on DNA by transplatin and trans-EE are relevant to their distinct clinical efficacy.

Institute of Biophysics Academy of Sciences of the Czech Republic Brno Czech Republic

Zobrazit více v PubMed

Biochemistry. 1991 Jan 8;30(1):222-30 PubMed

Biophys Chem. 1990 Apr;35(2-3):129-41 PubMed

Eur J Biochem. 1991 Dec 18;202(3):975-80 PubMed

Nucleic Acids Res. 1992 Jan 25;20(2):267-72 PubMed

Cancer Res. 1992 Sep 15;52(18):5065-72 PubMed

J Med Chem. 1993 Feb 19;36(4):510-2 PubMed

Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5345-9 PubMed

Biochemistry. 1993 Sep 21;32(37):9632-8 PubMed

Biochemistry. 1993 Nov 2;32(43):11676-81 PubMed

Nucleic Acids Res. 1994 Sep 25;22(19):3834-9 PubMed

Eur J Biochem. 1977 Sep;78(2):455-63 PubMed

Biochemistry. 1985 Jan 29;24(3):707-13 PubMed

Proc Natl Acad Sci U S A. 1985 Jul;82(14):4616-9 PubMed

Biochemistry. 1985 Dec 17;24(26):7533-40 PubMed

Cancer Res. 1987 Jan 1;47(1):31-6 PubMed

Biochemistry. 1987 Jun 16;26(12):3303-7 PubMed

Pharmacol Ther. 1987;34(2):155-66 PubMed

Nucleic Acids Res. 1988 May 25;16(10):4407-18 PubMed

Chem Biol Interact. 1988;67(1-2):71-80 PubMed

Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1982-5 PubMed

Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding

DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes